Agenus reports second quarter 2023 results

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers, today announced results for the second quarter 2023. key accomplishments and highlights include: botensilimab update: botensilimab/balstilimab combination data presented at esmo-gi demonstrated median overall survival (mos) of 20.9 months and a 23% overall response rate (orr), both surpassing data reported for standard of care in 3l+ non-msi-h col.
AGEN Ratings Summary
AGEN Quant Ranking